Gen-Probe (GPRO) Sees Double-Digit Revs Growth in FY12 on New Product Launches

Gen-Probe's (Nasdaq: GPRO) multiple new product launches are off to a good start and should help drive accelerating, double-digit revenue growth in 2012.

The following achievements will be discussed with investors at an upcoming JPMorgan health care conference:

• The Company achieved its goal of placing a few dozen PANTHER® systems with diagnostics customers outside the United States in 2011, with PANTHER-related revenues adding progressively more to growth over the course of the year.
  
  
• The Company's R&D priorities for 2012 include two significant instrument development programs that leverage the Company's automation expertise and intellectual property: adding real-time PCR capabilities for the next-generation PANTHER system, and developing a new instrument to further automate molecular testing from liquid-based cytology specimens.
  
  
• The Company has already recorded its first commercial sales of the APTIMA HPV assay, and is pleased with the high level of customer interest to date. More than 80 customers have adopted or are evaluating the APTIMA trichomonas assay, sales of which have increased on a sequential basis throughout 2011.
  The Company recently launched its CE-marked APTIMA trichomonas assay on the PANTHER system in Europe.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• GoPro promotes CFO Brian Tratt to senior vice president role
• Analog Devices (ADI) Tops Q3 EPS by 11c, Beats on Revenue; Offers Q4 Guidance
• Simmons Bank chief data officer Lisa Hunter to retire